• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by SciSparc Ltd. (Amendment)

    2/11/22 9:03:11 AM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SPRC alert in real time by email
    SC 13G/A 1 e621294_sc13ga-scisparc.htm

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

    ______________

     

    SCHEDULE 13G

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b) (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

     

    (Amendment No. 2)1

     

    SciSparc, Ltd.

    (Name of Issuer)

     

    Ordinary Shares, par value NIS 2.00 per share

    (Title of Class of Securities)

     

    88339A203

    (CUSIP Number)

     

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)

     

    ☒Rule 13d-1(c)

     

    ☐Rule 13d-1(d)

     

     

    ___________________________

    1 The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 88339A203

     

      1  

    NAME OF REPORTING PERSON

     
             
           

    Bigger Capital Fund, LP

     
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         6,125 Ordinary Shares*
    200,000 Ordinary Shares issuable upon exercise of Warrants (See Item 4)*
     
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              6,125 Ordinary Shares*
    200,000 Ordinary Shares issuable upon exercise of Warrants (See Item 4)*
     
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            6,125 Ordinary Shares*
    200,000 Ordinary Shares issuable upon exercise of Warrants (See Item 4)*
     
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            4.99%*  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    * As more fully described in Item 4, the Warrants are subject to a 4.99% blocker, and the percentage set forth in row (11) constitutes the percentage ownership of the Issuer’s outstanding Ordinary Shares, par value NIS 2.00 per share (the “Ordinary Shares”) held by the Reporting Person without reflecting for the exercise of the Warrants. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of Ordinary Shares that would be issuable upon the exercise of all such Warrants and do not give effect to such blockers. Therefore, the actual number of Ordinary Shares beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).

     

    2 

    CUSIP No. 88339A203

     

      1  

    NAME OF REPORTING PERSON

     
             
           

    Bigger Capital Fund GP, LLC

     
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         6,125 Ordinary Shares*
    200,000 Ordinary Shares issuable upon exercise of Warrants (See Item 4)*
     
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              6,125 Ordinary Shares*
    200,000 Ordinary Shares issuable upon exercise of Warrants (See Item 4)*
     
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            6,125 Ordinary Shares*
    200,000 Ordinary Shares issuable upon exercise of Warrants (See Item 4)*
     
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            4.99%*  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    * As more fully described in Item 4, the Warrants are subject to a 4.99% blocker, and the percentage set forth in row (11) constitutes the percentage ownership of the Issuer’s Ordinary Shares held by the Reporting Person without reflecting for the exercise of the Warrants. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of Ordinary Shares that would be issuable upon the exercise of all such Warrants and do not give effect to such blockers. Therefore, the actual number of Ordinary Shares beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).

     

    3 

    CUSIP No. 88339A203

     

      1  

    NAME OF REPORTING PERSON

     
             
           

    District 2 Capital Fund LP

     
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         20,040 Ordinary Shares
    200,000 Ordinary Shares issuable upon exercise of Warrants (See Item 4)*
     
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              20,040 Ordinary Shares
    200,000 Ordinary Shares issuable upon exercise of Warrants (See Item 4)*
     
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            20,040 Ordinary Shares
    200,000 Ordinary Shares issuable upon exercise of Warrants (See Item 4)*
     
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            4.99%*  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    * As more fully described in Item 4, the Warrants are subject to a 4.99% blocker, and the percentage set forth in row (11) constitutes the percentage ownership of the Issuer’s Ordinary Shares held by the Reporting Person without reflecting for the exercise of the Warrants. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of Ordinary Shares that would be issuable upon the exercise of all such Warrants and do not give effect to such blockers. Therefore, the actual number of Ordinary Shares beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).

     

    4 

    CUSIP No. 88339A203

     

      1  

    NAME OF REPORTING PERSON

     
             
           

    District 2 Capital LP

     
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         20,040 Ordinary Shares
    200,000 Ordinary Shares issuable upon exercise of Warrants (See Item 4)*
     
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              20,040 Ordinary Shares
    200,000 Ordinary Shares issuable upon exercise of Warrants (See Item 4)*
     
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            20,040 Ordinary Shares
    200,000 Ordinary Shares issuable upon exercise of Warrants (See Item 4)*
     
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            4.99%*  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    * As more fully described in Item 4, the Warrants are subject to a 4.99% blocker, and the percentage set forth in row (11) constitutes the percentage ownership of the Issuer’s Ordinary Shares held by the Reporting Person without reflecting for the exercise of the Warrants. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of Ordinary Shares that would be issuable upon the exercise of all such Warrants and do not give effect to such blockers. Therefore, the actual number of Ordinary Shares beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).

     

    5 

    CUSIP No. 88339A203

     

      1  

    NAME OF REPORTING PERSON

     
             
           

    District 2 GP LLC

     
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING        

    20,040 Ordinary Shares

    200,000 Ordinary Shares issuable upon exercise of Warrants (See Item 4)*

     
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
             

    20,040 Ordinary Shares

    200,000 Ordinary Shares issuable upon exercise of Warrants (See Item 4)*

     
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
           

    20,040 Ordinary Shares

    200,000 Ordinary Shares issuable upon exercise of Warrants (See Item 4)*

     
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            4.99%*  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    * As more fully described in Item 4, the Warrants are subject to a 4.99% blocker, and the percentage set forth in row (11) constitutes the percentage ownership of all of the Issuer’s Ordinary Shares held by the Reporting Person without reflecting for the exercise of the Warrants. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of Ordinary Shares that would be issuable upon the exercise of all such Warrants and do not give effect to such blockers. Therefore, the actual number of Ordinary Shares beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).

     

    6 

    CUSIP No. 88339A203

     

      1  

    NAME OF REPORTING PERSON

     
             
           

    District 2 Holdings LLC

     
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING        

    20,040 Ordinary Shares

    200,000 Ordinary Shares issuable upon exercise of Warrants (See Item 4)*

     
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
             

    20,040 Ordinary Shares

    200,000 Ordinary Shares issuable upon exercise of Warrants (See Item 4)*

     
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
           

    20,040 Ordinary Shares

    200,000 Ordinary Shares issuable upon exercise of Warrants (See Item 4)*

     
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            4.99%*  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    * As more fully described in Item 4, the Warrants are subject to a 4.99% blocker, and the percentage set forth in row (11) constitutes the percentage ownership of the Issuer’s Ordinary Shares held by the Reporting Person without reflecting for the exercise of the Warrants. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of Ordinary Shares that would be issuable upon the exercise of all such Warrants and do not give effect to such blockers. Therefore, the actual number of Ordinary Shares beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).

     

    7 

    CUSIP No. 88339A203

     

      1  

    NAME OF REPORTING PERSON

     
             
           

    Michael Bigger

     
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            USA  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         26,165 Ordinary Shares*
    400,000 Ordinary Shares issuable upon exercise of Warrants (See Item 4)*
     
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              26,165 Ordinary Shares*
    400,000 Ordinary Shares issuable upon exercise of Warrants (See Item 4)*
     
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            26,165 Ordinary Shares*
    400,000 Ordinary Shares issuable upon exercise of Warrants (See Item 4)*
     
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            4.99%*  
      12   TYPE OF REPORTING PERSON  
             
            IN  

      

    *As more fully described in Item 4, the Warrants are subject to a 4.99% blocker, and the percentage set forth in row (11) gives effect to such blockers. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of Ordinary Shares that would be issuable upon the exercise of all such Warrants and do not give effect to such blockers. Therefore, the actual number of Ordinary Shares beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).

     

    8 

    CUSIP No. 88339A203

     

    Item 1(a).Name of Issuer:

     

    SciSparc, Ltd., an Israeli corporation (the “Issuer”).

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    20 Raul Wallenberg Street, Tower A
    Tel Aviv 6971916, Israel

     

    Item 2(a).Name of Person Filing

     

    Item 2(b).Address of Principal Business Office or, if None, Residence

     

    Item 2(c).Citizenship

     

    Bigger Capital Fund, LP (“Bigger Capital”)

    2250 Red Springs Drive

    Las Vegas, NV 89135

    Citizenship: Delaware

     

    Bigger Capital Fund GP, LLC (“Bigger GP”)

    2250 Red Springs Drive

    Las Vegas, NV 89135

    Citizenship: Delaware

     

    District 2 Capital Fund LP (“District 2 CF”)

    175 W. Carver Street

    Huntington, NY 11743

    Citizenship: Delaware

     

    District 2 Capital LP (“District 2”)

    175 W. Carver Street

    Huntington, NY 11743

    Citizenship: Delaware

     

    District 2 GP LLC (“District 2 GP”)

    175 W. Carver Street

    Huntington, NY 11743

    Citizenship: Delaware

     

    District 2 Holdings LLC (“District 2 Holdings”)

    175 W. Carver Street

    Huntington, NY 11743

    Citizenship: Delaware

     

    Michael Bigger

    2250 Red Springs Drive

    Las Vegas, NV 89135

    Citizenship: USA

     

    Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”

     

    9 

    CUSIP No. 88339A203

     

    Item 2(d).Title of Class of Securities:

     

    Ordinary Shares, par value NIS 2.00 (the “Ordinary Shares”).

     

    Item 2(e).CUSIP Number:

     

    88339A203

     

    Item 3.If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     

        /x/ Not applicable.
           
      (a) / / Broker or dealer registered under Section 15 of the Exchange Act.
           
      (b) / / Bank as defined in Section 3(a)(6) of the Exchange Act.
           
      (c) / / Insurance company as defined in Section 3(a)(19) of the Exchange Act.
           
      (d) / / Investment company registered under Section 8 of the Investment Company Act.
           
      (e) / / An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
           
      (f) / / An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
           
      (g) / / A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
           
      (h) / / A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
           
      (i) / / A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
           
      (j) / / A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J).  
           
      (k) / / Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
           
          If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    10 

    CUSIP No. 88339A203

     

    Item 4.Ownership

     

    (a)Amount beneficially owned:

     

    As of December 31, 2021, Bigger Capital beneficially owned 6,125 Ordinary Shares and an aggregate of 200,000 Ordinary Shares currently issuable upon the exercise of Warrants (the “Warrants”). As described below, the Warrants contain a 4.99% beneficial ownership limitation.

     

    Bigger GP, as the general partner of Bigger Capital, may be deemed to beneficially own the (i) 6,125 Ordinary Shares and (ii) 200,000 Ordinary Shares issuable upon exercise of Warrants beneficially owned by Bigger Capital.

     

    As of December 31, 2021, District 2 CF beneficially owned 20,040 Ordinary Shares and 200,000 Ordinary Shares issuable upon the exercise of Warrants owned by District 2 CF. As described below, the Warrants contain a 4.99% beneficial ownership limitation.

     

    District 2, as the investment manager of District 2 CF, may be deemed to beneficially own the 20,040 Ordinary Shares beneficially owned by District 2 CF and the 200,000 Ordinary Shares issuable upon exercise of the Warrants beneficially owned by District 2 CF.

     

    District 2 GP, as the general partner of District 2 CF, may be deemed to beneficially own the 20,040 Ordinary Shares beneficially owned by District 2 CF and the 200,000 Ordinary Shares issuable upon exercise of the Warrants beneficially owned by District 2 CF.

     

    District 2 Holdings, as the managing member of District 2 GP, may be deemed to beneficially own the 20,040 Ordinary Shares beneficially owned by District 2 CF and the 200,000 Ordinary Shares issuable upon exercise of the Warrants beneficially owned by District 2 CF.

     

    Mr. Bigger, as the managing member of Bigger GP may be deemed to beneficially own the (i) 6,125 Ordinary Shares beneficially owned by Bigger Capital, (ii) 200,000 Ordinary Shares issuable upon exercise of Warrants owned by Bigger Capital, (iii) 20,040 Ordinary Shares beneficially owned by District 2 CF, and (iv) 200,000 Ordinary Shares issuable upon exercise of Warrants owned by District 2 CF.

     

    The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any Ordinary Shares owned by another Reporting Person. Each of Bigger GP and Mr. Bigger disclaims beneficial ownership of the Ordinary Shares beneficially owned by Bigger Capital. Each of District 2, District 2 GP, District 2 Holdings and Mr. Bigger disclaim beneficial ownership of the Ordinary Shares owned by District 2 CF.The filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.

     

    (b)Percent of class:

     

    The following percentages are based on 3,091,740 Ordinary Shares outstanding as of January 5, 2021, based on information in the Issuer’s Proxy Statement filed under Form 6-K on January 6, 2022 with the Securities and Exchange Commission.

     

    11 

    CUSIP No. 88339A203

     

    As of the close of business on December 31, 2021, each of Bigger Capital, Bigger GP, District 2, District 2 GP, District CF and District 2 Holdings and Mr. Bigger may be deemed to beneficially own 4.99% of the outstanding Ordinary Shares.

     

    Pursuant to the terms of the Warrants, the Reporting Persons cannot exercise the Warrants to the extent the Reporting Persons or affiliates of the Reporting Persons would beneficially own, after any such exercise, more than 4.99% of the outstanding Ordinary Shares (the “Blocker”), and the percentage set forth in Row 11 of the cover page for each Reporting Person as well in this Item 4(b) gives effect to the Blocker.

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote

     

    See Cover Pages Items 5-9.

     

    (ii)Shared power to vote or to direct the vote

     

    See Cover Pages Items 5-9.

     

    (iii)Sole power to dispose or to direct the disposition of

     

    See Cover Pages Items 5-9.

     

    (iv)Shared power to dispose or to direct the disposition of

     

    See Cover Pages Items 5-9.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof, the Reporting Person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☒

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not Applicable.

     

    Item 7.Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    See Exhibit 99.1.

     

    Item 9.Notice of Dissolution of Group.

     

    Not Applicable.

     

    Item 10.Certifications.

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    12 

    CUSIP No. 88339A203

     

    SIGNATURE

     

    After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: February 11, 2022

      

    BIGGER CAPITAL FUND, LP   BIGGER CAPITAL FUND GP, LLC
         
    By: Bigger Capital Fund GP, LLC, its general partner   By: /s/ Michael Bigger
            Michael Bigger
    By: /s/ Michael Bigger     Managing Member
      Michael Bigger      
      Managing Member      
          DISTRICT 2 CAPITAL LP
             
    DISTRICT 2 CAPITAL FUND LP   By: /s/ Michael Bigger
            Michael Bigger
    By: District 2 GP LLC, its general partner     Managing Member
             
    By: /s/ Michael Bigger      
      Michael Bigger   DISTRICT 2 HOLDINGS LLC
      Managing Member      
          By: /s/ Michael Bigger
            Michael Bigger
    DISTRICT 2 GP LLC     Managing Member
             
    By: /s/ Michael Bigger      
      Michael Bigger   /s/ Michael Bigger
      Managing Member   MICHAEL BIGGER

      

     

    Get the next $SPRC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SPRC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SPRC
    Financials

    Live finance-specific insights

    See more
    • SciSparc Adopts Limited Duration Shareholder Rights Plan

      TEL AVIV, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its Board of Directors (the "Board") has unanimously adopted a limited duration shareholder rights plan (the "Rights Plan"), effective immediately. "Today we announced exciting positive results from our weight loss and metabolic disorder program with our proprietary psychedelic-based treatment," said Oz Adler, SciSparc's Chief Executive Officer. "Unfortunately, SciSparc, like many other clinical-stag

      11/28/23 8:55:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SciSparc Signs Non-Binding Letter of Intent to Merge with Leading Vehicle Importer Company in Israel

      SciSparc seeks to scale up revenues and will consider transferring its pharmaceutical activities to a separate legal entity and exploring the possibility of dividend distribution TEL AVIV, Israel, Nov. 22, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today the signing of a non-binding letter of intent to merge with a leading vehicle importer company in Israel (the "Target Company"). This merger (the "Merger) is expected to be consummated by means of a reverse triangular merger, pursua

      11/22/23 7:42:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split

      Following the reverse share split, the Company will have approximately 521,090 Ordinary Shares issued and outstanding TEL AVIV, Israel, Sept. 27, 2023 (GLOBE NEWSWIRE) --  SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announces today that its previously announced reverse share split of its issued and outstanding ordinary shares, no par value at a ratio of 1-for-26, is expected to be implemented after market close today. The Company's Ordinary Shares will begin trading on the Nasdaq Capital Market on a post-split basis at

      9/27/23 7:58:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRC
    SEC Filings

    See more
    • Amendment: SEC Form F-4/A filed by SciSparc Ltd.

      F-4/A - SciSparc Ltd. (0001611746) (Filer)

      4/28/25 7:11:58 PM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by SciSparc Ltd.

      S-8 - SciSparc Ltd. (0001611746) (Filer)

      4/28/25 8:56:08 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by SciSparc Ltd.

      6-K - SciSparc Ltd. (0001611746) (Filer)

      4/25/25 8:19:42 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRC
    Leadership Updates

    Live Leadership Updates

    See more
    • SciSparc Makes Another Step Towards Unlocking Potential Value Appoints New Strategy and Business Development VP

      As part of the Company's corporate restructuring plan, Mr. Yaki Baranes will facilitate identifying new business opportunities TEL AVIV, Israel, May 30, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that as part of its restructuring plans to unlock value for shareholders, it has appointed a new Vice President of Strategy and Business Development, Mr. Yaki Baranes, to structure business strategies and facilitate identifying new business opportunities. Mr. Baranes is a business strategy expert with a

      5/30/23 8:40:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SciSparc Reinforces its New JV for Targeting Discovery with a Global Expert in the Field of Mitochondrial Transport Proteins

      JV Targets Potential Drugs for Cancers and Infectious Diseases Tel Aviv, Israel, June 15, 2022 (GLOBE NEWSWIRE) --  SciSparc Ltd. (NASDAQ:SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the appointment of Prof. Ciro Leonardo Pierri as special advisor for MitoCareX Bio Ltd. ("MitoCareX Bio"), SciSparc's recently established joint venture ("JV") for the discovery and development of potential drugs for cancers, infectious diseases and other life-threatening conditions. Prof. Pierri is a biochemist and serves as an associate professor at the U

      6/15/22 8:30:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prof. Avi Schroeder Joins SciSparc's Scientific Advisory Board to Support the Company's Development of SCI-160 for Treating Pain

      Prof. Schroeder to advise on SCI-160 formulation development to enhance biological effect and extended effect duration TEL AVIV, Israel, March 30, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced the appointment of Professor Avi Schroeder as a member of the Company's Scientific Advisory Board (SAB). As a member of the SAB, Prof. Schroeder will support the development of the Company's top-tier, proprietary, investigational drug candidate SCI-160 program for the treatment of pain. Prof. Schroed

      3/30/22 8:30:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by SciSparc Ltd.

      SC 13G - SciSparc Ltd. (0001611746) (Subject)

      3/6/24 5:02:18 PM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by SciSparc Ltd.

      SC 13G - SciSparc Ltd. (0001611746) (Filed by)

      12/13/22 6:22:30 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by SciSparc Ltd. (Amendment)

      SC 13G/A - SciSparc Ltd. (0001611746) (Subject)

      5/9/22 4:08:30 PM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

      TEL AVIV, Israel, April 25, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (NASDAQ:CMND) has led to the filing of a new international patent application for a proprietary treatment targeting anorexia, bulimia and other eating disorders. The patent application covers the use of 3-Methylmethcathinone (3-MMC) in combination with SciSparc's Palmitoylethanolamide ("PEA"). This innovative combination aims to address the complex neurobiological and psych

      4/25/25 7:59:00 AM ET
      $CMND
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea

      TEL AVIV, Israel, March 10, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (NASDAQ:CMND) has led to the publication of a patent application by the South Korean Intellectual Property Office ("KIPO"). The patent application relates to a combination treatment using Clearmind's 5-methoxy-2-aminoindane ("MEAI") and SciSparc's Palmitoylethanolamide ("PEA") for the treatment of cocaine addiction. The patent is based on preclinical trial results led by P

      3/10/25 7:45:00 AM ET
      $CMND
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea

      Vancouver, Canada, March 10, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of a patent by the Korean Intellectual Property Office (KIPO), South Korea's official patent and intellectual property authority. The patent covers the Company's innovative combination therapy of MEAI and N-Acylethanolamines for the treatment of cocaine addiction. The patent is based on preclinical trial results led by Professor Gal Yadid and his team at the Gonda Mu

      3/10/25 7:27:00 AM ET
      $CMND
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care